Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity in Relapsed and Refractory Non-Hodgkin’s Lymphoma

Flavopiridol is a broad cyclin-dependent kinase inhibitor (CDKI) that induces apoptosis of malignant lymphocytes in vitro and in murine lymphoma models. We conducted a phase I dose-escalation study to determine the maximum tolerated dose (MTD) for single-agent flavopiridol administered on a pharmaco...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Jones, Jeffrey A., Rupert, Amy S., Poi, Ming, Phelps, Mitch A., Andritsos, Leslie, Baiocchi, Robert, Benson, Don M., Blum, Kristie A., Christian, Beth, Flynn, Joseph, Penza, Sam, Porcu, Pierluigi, Grever, Michael R., Byrd, John C.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4150545/
https://ncbi.nlm.nih.gov/pubmed/23959599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23568
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items